Covered recipient · General Payments record
PRZEMYSLAW W TWARDOWSKI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$122,114.34
174 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,435.00 | 26 |
| Travel and Lodging | $16,190.02 | 62 |
| Consulting Fee | $14,672.50 | 5 |
| Food and Beverage | $3,716.87 | 80 |
| Education | $99.95 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $33,472.87 | 29 |
| Bayer HealthCare Pharmaceuticals Inc. | $21,491.93 | 43 |
| Astellas Pharma US Inc | $20,948.25 | 23 |
| Janssen Biotech, Inc. | $19,316.21 | 27 |
| PFIZER INC. | $17,738.89 | 13 |
| E.R. Squibb & Sons, L.L.C. | $3,497.23 | 6 |
| Clovis Oncology, Inc. | $3,295.49 | 7 |
| Astellas Pharma Global Development | $1,395.00 | 1 |
| Merck Sharp & Dohme Corporation | $235.89 | 12 |
| Genentech USA, Inc. | $185.23 | 2 |
| AstraZeneca UK Limited | $152.30 | 2 |
| Osiris Therapeutics Inc. | $124.22 | 2 |
| Seattle Genetics, Inc. | $99.95 | 1 |
| Janssen Scientific Affairs, LLC | $64.57 | 1 |
| Array BioPharma Inc. | $46.63 | 2 |
| Regeneron Healthcare Solutions, Inc. | $24.11 | 1 |
| Smith+Nephew, Inc. | $13.87 | 1 |
| Dendreon Pharmaceuticals LLC | $11.70 | 1 |
Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PRZEMYSLAW W TWARDOWSKI
NPI 1942317987 · CMS profile ID 269277
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
SANTA MONICA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- PRZEMYSLAW W TWARDOWSKI, NPI 1942317987, CMS profile ID 269277, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 174 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1942317987?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
174 matching records · $122,114.34 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 174.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $8.47 | 05/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694232441 | CMS |
| GENZYME CORPORATION | $40.00 | 05/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694315969 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3,120.00 | 05/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491547 | CMS |
| Smith+Nephew, Inc. | $13.87 | 05/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 699423133 | CMS |
| Merck Sharp & Dohme Corporation | $19.33 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695827255 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $144.63 | 04/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628448109 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $144.63 | 04/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628453609 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $2,880.00 | 04/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628468629 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5,760.00 | 04/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491461 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $186.10 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628433951 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $76.86 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628426495 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $734.50 | 04/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628476749 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $15.30 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628411947 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $12.84 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628416561 | CMS |
| Osiris Therapeutics Inc. | $4.12 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697624451 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,910.00 | 04/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628428151 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $328.72 | 04/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628492603 | CMS |
| Merck Sharp & Dohme Corporation | $35.40 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695438785 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $63.65 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628466151 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.50 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628479035 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $45.00 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491787 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $63.65 | 04/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628492289 | CMS |
| PFIZER INC. | $4,400.00 | 04/10/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673201427 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $60.00 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628460347 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $38.40 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628422229 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $47.27 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628422843 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $160.00 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628424661 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $24.31 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628436891 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $80.00 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628470945 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $5.56 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628474553 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $49.41 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628475435 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $54.02 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628484153 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $7.34 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491403 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $22.96 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491491 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $4,250.00 | 04/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491609 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $3.08 | 04/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709112687 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $125.10 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628467861 | CMS |
| PFIZER INC. | $415.80 | 04/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673216669 | CMS |
| Osiris Therapeutics Inc. | $120.10 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697622901 | CMS |
| E.R. Squibb & Sons, L.L.C. | $127.40 | 04/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351937 | CMS |
| PFIZER INC. | $93.39 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673211583 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,587.50 | 03/29/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351935 | CMS |
| Janssen Biotech, Inc. | $57.97 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658761047 | CMS |
| E.R. Squibb & Sons, L.L.C. | $265.07 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351961 | CMS |
| E.R. Squibb & Sons, L.L.C. | $370.80 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351963 | CMS |
| E.R. Squibb & Sons, L.L.C. | $119.19 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351971 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651351981 | CMS |
| Astellas Pharma US Inc | $91.43 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655785611 | CMS |
| Astellas Pharma US Inc | $3,325.00 | 03/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655785615 | CMS |
| Astellas Pharma US Inc | $48.60 | 03/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655785619 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $314.64 | 2 |
| PY2025 | Principal investigator | $1,121,216.60 | 157 |
| PY2024 | Recipient | $191.83 | 1 |
| PY2024 | Principal investigator | $944,798.82 | 152 |
| PY2023 | Principal investigator | $1,438,293.19 | 94 |
| PY2022 | Principal investigator | $606,833.96 | 48 |
| PY2021 | Principal investigator | $1,100,735.70 | 75 |
| PY2020 | Principal investigator | $523,039.35 | 167 |
| PY2019 | Principal investigator | $224,500.20 | 190 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
159 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 12/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411618 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $18,435.62 | 12/31/2025 | Non-covered Recipient Entity Providence Saint John's Health Center | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926693 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,150.54 | 12/31/2025 | Non-covered Recipient Entity John Wayne Cancer Institute | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- | No dispute reported | 06/30/2026 | 1232927699 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,878.00 | 12/31/2025 | Non-covered Recipient Entity Providence Saint John's Health Center | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1232931216 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $540.00 | 12/16/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411626 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 12/16/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411652 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 12/16/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411716 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411642 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,889.00 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411676 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $395.00 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411682 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411698 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411710 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,589.00 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411718 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411720 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $253.50 | 12/10/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411742 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 12/01/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411606 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 12/01/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411624 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 12/01/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411656 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 12/01/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411684 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 12/01/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411696 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $62,755.64 | 12/01/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1190303123 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 11/14/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409560 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 11/14/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409806 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 11/14/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409838 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409920 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409924 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409998 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $108.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410040 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $150.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410062 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410076 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410192 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410212 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410228 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/31/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410248 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 10/27/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409974 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 10/15/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410256 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 10/15/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410292 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,705.79 | 10/15/2025 | Non-covered Recipient Entity PROVIDENCE SAINT JOHNS HEALTH CENTER | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190305247 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409938 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 10/03/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409976 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409996 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,542.00 | 09/18/2025 | Non-covered Recipient Entity Providence Saint John's Health Center | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | No dispute reported | 06/30/2026 | 1232926691 |
| Principal investigator 1 | Organon Llc | $468.00 | 09/18/2025 | Non-covered Recipient Entity John Wanye Cancer Institute | 3475-587 | No dispute reported | 06/30/2026 | 1173042718 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410382 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410468 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410534 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410754 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410782 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411006 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411024 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 09/17/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411378 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $211.54 | 09/12/2025 | Covered Recipient Physician | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184123622 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $44.55 | 08/14/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184228461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,081.35 | 08/14/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184228463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.90 | 08/14/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184228465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,988.28 | 07/08/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184213365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,700.00 | 06/18/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180445 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $82,800.00 | 06/10/2025 | Non-covered Recipient Entity Saint John's Cancer Institute | A Phase 1,1b, Open-Label, Study of ANK-101 Administered as a Single Agent in Participants with Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors or in Combination with Pembrolizumab in Participants with Advanced Mucosal Melanoma | No dispute reported | 06/30/2026 | 1232932417 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 06/04/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407946 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 06/04/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408004 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 06/04/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408478 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 06/04/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408496 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407400 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407402 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407406 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407414 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407428 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $400.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407448 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407470 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407510 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $250.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407512 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407518 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407520 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407528 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407530 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $400.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407538 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407540 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407548 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407550 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407556 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407564 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407566 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407568 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407642 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407646 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407648 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407670 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407688 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $279.31 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407702 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407712 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $60.00 | 05/26/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407776 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 05/21/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407786 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,516.00 | 04/28/2025 | Non-covered Recipient Entity PROVIDENCE SAINT JOHNS HEALTH CENTER | A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer | No dispute reported | 06/30/2026 | 1190305243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,076.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,677.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,760.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180454 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,124.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180484 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,688.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180491 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,739.00 | 04/24/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180690 |
| Principal investigator 1 | Janssen Research & Development, LLC | $519.00 | 04/11/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $519.00 | 04/11/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,625.00 | 04/11/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $338.00 | 04/11/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180575 |
| Principal investigator 1 | Janssen Research & Development, LLC | $519.00 | 04/11/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180682 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 03/24/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403181 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 03/24/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225407020 |
| Principal investigator 1 | AstraZeneca UK Limited | $75,696.63 | 03/05/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185553581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,947.00 | 03/05/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180415 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $103.10 | 03/04/2025 | Covered Recipient Physician | A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression | No dispute reported | 06/30/2026 | 1184123620 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402513 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402515 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402727 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,589.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402951 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402953 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402955 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402963 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403103 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403535 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403659 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403661 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403673 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404046 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404321 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404602 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404604 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404956 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404958 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405018 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405352 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405354 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405416 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405580 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405582 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,956.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405584 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,956.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405874 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406258 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406342 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406344 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406346 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406348 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,956.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406360 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406362 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406364 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406416 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406636 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406638 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406686 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406688 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406690 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406716 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,595.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406718 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,478.00 | 02/28/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406880 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,986.44 | 02/14/2025 | Non-covered Recipient Entity Saint Johns Cancer Inst | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175180290 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $172,576.91 | 02/05/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185553583 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 02/05/2025 | Non-covered Recipient Entity Providence Saint John's Health Center | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Therapy | No dispute reported | 06/30/2026 | 1232931024 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,286.95 | 01/29/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403781 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $405.00 | 01/29/2025 | Non-covered Recipient Entity New Mexico Cancer Center Admin Office | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405626 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $69,547.90 | 01/15/2025 | Non-covered Recipient Entity PROVIDENCE SAINT JOHNS HEALTH CENTER | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190305245 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $206,658.00 | 01/07/2025 | Non-covered Recipient Entity SAINT JOHNS CANCER INSTITUTE | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190304135 |